Journal
FUTURE ONCOLOGY
Volume 11, Issue 20, Pages 2807-2818Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon.15.191
Keywords
bortezomib; immunochemotherapy; mantle cell lymphoma; novel agents; Phase III; safety; stem cell transplantation
Categories
Funding
- Medical University of Lodz [503/1-1093-01/503-01]
- Foundation for the Development of Diagnostics and Therapy, Warsaw, Poland
- Janssen Cilag
Ask authors/readers for more resources
Mantle cell lymphoma (MCL) is a hematological malignancy with unfavorable prognosis. Bortezomib, a potent, selective and reversible inhibitor of the 26S proteasome, was shown to be active in MCL and is currently implemented in therapeutic combinations. Single-agent bortezomib has demonstrated clinical efficacy in relapsed and refractory MCL with objective response in up to 47% of the patients. However, complete remission rates are low and duration of response is relatively short. In previously untreated patients, the addition of bortezomib to induction chemotherapy is also promising. Further evaluation of bortezomib alone or in combination with other drugs for the treatment of MCL is warranted to improve the quality of life and survival of patients. This review explores bortezomib as therapy in patients with MCL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available